{"protocolSection":{"identificationModule":{"nctId":"NCT00888511","orgStudyIdInfo":{"id":"09.02"},"organization":{"fullName":"Odense University Hospital","class":"OTHER"},"briefTitle":"Tarceva And Radiotherapy in Locally Advanced Lung Cancer Non-small Cell Lung Cancer","officialTitle":"Concomitant Tarceva® and Irradiation in Patients in Local-regionally Advanced Non-small Cell Lung Cancer. A Phase II Study","acronym":"TARLAL"},"statusModule":{"statusVerifiedDate":"2020-11","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2009-05"},"primaryCompletionDateStruct":{"date":"2016-05","type":"ACTUAL"},"completionDateStruct":{"date":"2016-05","type":"ACTUAL"},"studyFirstSubmitDate":"2009-04-24","studyFirstSubmitQcDate":"2009-04-24","studyFirstPostDateStruct":{"date":"2009-04-27","type":"ESTIMATED"},"resultsFirstSubmitDate":"2017-04-06","resultsFirstSubmitQcDate":"2020-11-04","resultsFirstPostDateStruct":{"date":"2020-11-27","type":"ACTUAL"},"lastUpdateSubmitDate":"2020-11-04","lastUpdatePostDateStruct":{"date":"2020-11-27","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR_INVESTIGATOR","investigatorFullName":"Olfred Hansen","investigatorTitle":"MD","investigatorAffiliation":"Odense University Hospital"},"leadSponsor":{"name":"Olfred Hansen","class":"OTHER"},"collaborators":[{"name":"Odense University Hospital","class":"OTHER"},{"name":"Copenhagen University Hospital at Herlev","class":"OTHER"},{"name":"Rigshospitalet, Denmark","class":"OTHER"},{"name":"Aalborg University Hospital","class":"OTHER"},{"name":"Aarhus University Hospital","class":"OTHER"},{"name":"Naestved Hospital","class":"OTHER"}]},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"The trial is a phase II study of daily Tarceva combined with definitive radiotherapy in inoperable locally advanced non small cell lung cancer (stage IIB-IIIB). The objective of the phase II trial is to examine Tarceva concomitant with curatively intended irradiation 66 Gy (2 Gy x 33 F, 5 F per week)."},"conditionsModule":{"conditions":["Non-small Cell Lung Cancer"],"keywords":["Lung cancer","Non-small cell lung cancer","Tarceva","Radiotherapy","Local-regionally advanced non-small cell lung cancer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":15,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: Tarceva","Radiation: Radiotherapy"]}],"interventions":[{"type":"DRUG","name":"Tarceva","description":"Tarceva 150 mg/day","armGroupLabels":["1"]},{"type":"RADIATION","name":"Radiotherapy","description":"66 Gy/33 F/5 F per week for 5 weeks","armGroupLabels":["1"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Progression Free Survival","description":"Progression free survival from registration according to RECIST 1.1","timeFrame":"3 years"}],"secondaryOutcomes":[{"measure":"Toxicity","timeFrame":"3 years"},{"measure":"Local Tumor Control by CT-scan","timeFrame":"May 2012"},{"measure":"Overall Response Rate (CR + PR)","timeFrame":"May 2012"},{"measure":"Local Tumor Control at 9 Months Evaluated by PET-CT","timeFrame":"May 2012"},{"measure":"Overall Survival","timeFrame":"May 2012"},{"measure":"Disease Free Survival","timeFrame":"May 2012"},{"measure":"Late Toxicity","timeFrame":"May 2012"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age ≥18 years\n* Patients with histologically or cytologically documented diagnosis locally advanced NSCLC stage IIB to IIIB without pleural effusion\n* Performance status ≤2 on the ECOG scale\n* Serum bilirubin must be ≤1.5 upper limit of normal (ULN)\n* ALAT ≤2 x ULN\n* Able to comply with study and follow-up procedures\n* Patients with reproductive potential must use effective contraception\n* Written (signed) informed consent to participate in the study\n\nExclusion Criteria:\n\n* Any unstable systemic disease (including active infection, unstable angina, congestive heart failure, severe hepatic, renal, or metabolic disease)\n* Any other malignancies within 5 years (except for adequately treated carcinoma in situ of the cervix or basal or squamous cell skin cancer)\n* Inability to take oral medication, or requirement of intravenous alimentation\n* Nursing mothers","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"90 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Olfred Hansen, MD","affiliation":"Odense University Hospital","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Department of Oncology, Aarhus University Hospital","city":"Aarhus","zip":"8000","country":"Denmark","geoPoint":{"lat":56.15674,"lon":10.21076}},{"facility":"Department of Oncology, Rigshospitalet","city":"Copenhagen","zip":"2100","country":"Denmark","geoPoint":{"lat":55.67594,"lon":12.56553}},{"facility":"Department of Oncology, Copenhagen University Hospital at Herlev","city":"Herlev","zip":"270","country":"Denmark","geoPoint":{"lat":55.72366,"lon":12.43998}},{"facility":"Department of Oncology, Naestved Hospital","city":"Næstved","country":"Denmark","geoPoint":{"lat":55.22992,"lon":11.76092}},{"facility":"Laboratory of Radiation Physics","city":"Odense","zip":"5000","country":"Denmark","geoPoint":{"lat":55.39594,"lon":10.38831}},{"facility":"Odense University Hospital","city":"Odense","zip":"5000","country":"Denmark","geoPoint":{"lat":55.39594,"lon":10.38831}},{"facility":"Department of Oncology, Vejle Hospital","city":"Vejle","zip":"7100","country":"Denmark","geoPoint":{"lat":55.70927,"lon":9.5357}}]}},"resultsSection":{"participantFlowModule":{"recruitmentDetails":"July 2007 - November 2013","groups":[{"id":"FG000","title":"Concurrent Tarceva and RT in LA-NSCLC","description":"Tarceva: Tarceva 150 mg/day\n\nRadiotherapy: 66 Gy/33 F/5 F per week for 5 weeks"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"15"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"15"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Concurrent Tarceva and RT in LA-NSCLC","description":"Tarceva: Tarceva 150 mg/day\n\nRadiotherapy: 66 Gy/33 F/5 F per week for 5 weeks"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"15"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEDIAN","dispersionType":"FULL_RANGE","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"75","lowerLimit":"49","upperLimit":"85"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"6"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"9"}]}]}]},{"title":"Region of Enrollment","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"Denmark","categories":[{"measurements":[{"groupId":"BG000","value":"15"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Progression Free Survival","description":"Progression free survival from registration according to RECIST 1.1","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"months","timeFrame":"3 years","groups":[{"id":"OG000","title":"Concurrent Tarceva and RT in LA-NSCLC","description":"Tarceva: Tarceva 150 mg/day\n\nRadiotherapy: 66 Gy/33 F/5 F per week for 5 weeks"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.4","lowerLimit":"1.7","upperLimit":"68"}]}]}]},{"type":"SECONDARY","title":"Toxicity","reportingStatus":"NOT_POSTED","timeFrame":"3 years","denomUnitsSelected":"Participants"},{"type":"SECONDARY","title":"Local Tumor Control by CT-scan","reportingStatus":"NOT_POSTED","timeFrame":"May 2012","denomUnitsSelected":"Participants"},{"type":"SECONDARY","title":"Overall Response Rate (CR + PR)","reportingStatus":"NOT_POSTED","timeFrame":"May 2012","denomUnitsSelected":"Participants"},{"type":"SECONDARY","title":"Local Tumor Control at 9 Months Evaluated by PET-CT","reportingStatus":"NOT_POSTED","timeFrame":"May 2012","denomUnitsSelected":"Participants"},{"type":"SECONDARY","title":"Overall Survival","reportingStatus":"NOT_POSTED","timeFrame":"May 2012","denomUnitsSelected":"Participants"},{"type":"SECONDARY","title":"Disease Free Survival","reportingStatus":"NOT_POSTED","timeFrame":"May 2012","denomUnitsSelected":"Participants"},{"type":"SECONDARY","title":"Late Toxicity","reportingStatus":"NOT_POSTED","timeFrame":"May 2012","denomUnitsSelected":"Participants"}]},"adverseEventsModule":{"frequencyThreshold":"5","eventGroups":[{"id":"EG000","title":"Concurrent Tarceva and RT in LA-NSCLC","description":"Tarceva: Tarceva 150 mg/day\n\nRadiotherapy: 66 Gy/33 F/5 F per week for 5 weeks","deathsNumAffected":15,"deathsNumAtRisk":15,"seriousNumAffected":3,"seriousNumAtRisk":15,"otherNumAffected":0,"otherNumAtRisk":15}],"seriousEvents":[{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":15}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":false},"pointOfContact":{"title":"Olfred Hansen","organization":"Odense University Hospital","email":"olfred.hansen@rsyd.dk","phone":"+45 2424 1588"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"},{"id":"D008175","term":"Lung Neoplasms"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000069347","term":"Erlotinib Hydrochloride"},{"id":"D011878","term":"Radiotherapy"}],"ancestors":[{"id":"D011799","term":"Quinazolines"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D013812","term":"Therapeutics"}]}},"hasResults":true}